What is Bit Bio?
Bit Bio is a pioneering synthetic biology enterprise that specializes in the generation of highly defined, mature human cell types. By leveraging its patented opti-ox gene-targeting technology, the company enables the precise reprogramming of human induced pluripotent stem cells (iPSCs). This technological breakthrough provides researchers and pharmaceutical developers with consistent, scalable access to human cells, which is essential for advancing drug discovery and developing next-generation cell therapies. By bridging the gap between laboratory-scale innovation and industrial-grade production, Bit Bio is effectively addressing the reproducibility challenges that have historically hindered the life sciences industry.
How much funding has Bit Bio raised?
Bit Bio has raised a total of $255M across 6 funding rounds:
Angel/Seed
$471K
Series A
$41.5M
Series B
$103M
Other Financing Round
$30M
Private Equity
$30M
Series C
$50M
Angel/Seed (2017): $471K with participation from Jonathan Milner
Series A (2020): $41.5M led by Arch Venture Partners, Foresite Capital, Richard Klausner, and Blueyard Capital
Series B (2021): $103M supported by Foresite Capital, Charles River Laboratories, Arch Ventures, and National Resilience
Other Financing Round (2024): $30M featuring M&G Investments, ARCH Venture Partners, and Tencent
Private Equity (2024): $30M backed by BlueYard Capital, Puhua Capital, ARCH Venture Partners, and M&G
Series C (2026): $50M with participation from M&G
Key Investors in Bit Bio
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data, targeting breakthrough opportunities at the intersection of technology and biotechnology.
M&G
M&G plc is an international savings, investment, asset management, and insurance company headquartered in London, providing comprehensive financial solutions to individual and institutional clients across multiple global markets.
What's next for Bit Bio?
With the infusion of recent capital, Bit Bio is well-positioned to expand its operational footprint and deepen its pipeline of therapeutic candidates. The strategic focus will likely center on scaling the manufacturing of its cell products to meet the growing demand from global pharmaceutical partners and academic institutions. Furthermore, the company is expected to leverage its robust balance sheet to enhance its R&D infrastructure, potentially exploring new applications for its transcription factor-based reprogramming platform. As the firm matures, the emphasis will shift toward clinical validation and the commercialization of its proprietary cell lines, aiming to set a new standard for precision in regenerative medicine and disease modeling.
See full Bit Bio company page
